Acquired Pure Red Cell Aplasia Following Recombinant Erythropoietin (Darbepoetin-alfa) Therapy

Somanath Padhi; Gayatri Behera; Sandeep Abhijit Pattnaik; Prabodh Kumar Das; Amit Kumar Adhya; Susama Patra

doi:10.4103/ijn.IJN_129_19

Acquired Pure Red Cell Aplasia Following Recombinant Erythropoietin (Darbepoetin-alfa) Therapy

Indian J Nephrol. 2020 Mar-Apr;30(2):113-116. doi: 10.4103/ijn.IJN_129_19. Epub 2019 Sep 6.

Authors

Somanath Padhi¹, Gayatri Behera¹, Sandeep Abhijit Pattnaik¹, Prabodh Kumar Das², Amit Kumar Adhya¹, Susama Patra¹

Affiliations

¹ Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
² Department of Medical Oncology/Hematology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.

Abstract

Acquired pure red cell aplasia (PRCA) following use of recombinant erythropoietin (rEPO) is distinctly rare and sporadically reported in the literature. We discuss a case of PRCA following the usage of rEPO (darbepoetin-α) during the management of anemia of chronic kidney disease in an elderly male subject with review of literature and a brief insight into proposed pathophysiologic mechanism, diagnosis, and management.

Keywords: Anti-EPO antibody; erythropoiesis; erythropoietic stimulating agents.

Publication types

Case Reports